HappeningToo topic
Galcanezumab-gnlm reports
Browse community reports connected to Galcanezumab-gnlm. These reports can show that other people are describing similar experiences, but they do not prove that Galcanezumab-gnlm caused a symptom or reaction.
⚕️ Medicine safety note
Community reports do not prove causation, cannot be used to estimate how common a reaction is, and are not medical advice.
40 problems
Abdominal Discomfort while using Galcanezumab-gnlm
FDA FAERS contains adverse-event reports in which Galcanezumab-gnlm and abdominal discomfort appear together. This does not establish that Galcanezumab-gnlm caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Abdominal Distension while using Galcanezumab-gnlm
FDA FAERS contains adverse-event reports in which Galcanezumab-gnlm and abdominal distension appear together. This does not establish that Galcanezumab-gnlm caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Abdominal Pain Upper while using Galcanezumab-gnlm
FDA FAERS contains adverse-event reports in which Galcanezumab-gnlm and abdominal pain upper appear together. This does not establish that Galcanezumab-gnlm caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Abdominal Pain while using Galcanezumab-gnlm
FDA FAERS contains adverse-event reports in which Galcanezumab-gnlm and abdominal pain appear together. This does not establish that Galcanezumab-gnlm caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Alopecia while using Galcanezumab-gnlm
FDA FAERS contains adverse-event reports in which Galcanezumab-gnlm and alopecia appear together. This does not establish that Galcanezumab-gnlm caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Anxiety while using Galcanezumab-gnlm
FDA FAERS contains adverse-event reports in which Galcanezumab-gnlm and anxiety appear together. This does not establish that Galcanezumab-gnlm caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Back Pain while using Galcanezumab-gnlm
FDA FAERS contains adverse-event reports in which Galcanezumab-gnlm and back pain appear together. This does not establish that Galcanezumab-gnlm caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Constipation while using Galcanezumab-gnlm
FDA FAERS contains adverse-event reports in which Galcanezumab-gnlm and constipation appear together. This does not establish that Galcanezumab-gnlm caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Cough while using Galcanezumab-gnlm
FDA FAERS contains adverse-event reports in which Galcanezumab-gnlm and cough appear together. This does not establish that Galcanezumab-gnlm caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Diarrhea while using Galcanezumab-gnlm
FDA FAERS contains adverse-event reports in which Galcanezumab-gnlm and diarrhea appear together. This does not establish that Galcanezumab-gnlm caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Dizziness while using Galcanezumab-gnlm
FDA FAERS contains adverse-event reports in which Galcanezumab-gnlm and dizziness appear together. This does not establish that Galcanezumab-gnlm caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Excessive sweating while using Galcanezumab-gnlm
FDA FAERS contains adverse-event reports in which Galcanezumab-gnlm and excessive sweating appear together. This does not establish that Galcanezumab-gnlm caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Fatigue while using Galcanezumab-gnlm
FDA FAERS contains adverse-event reports in which Galcanezumab-gnlm and fatigue appear together. This does not establish that Galcanezumab-gnlm caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Feeling Abnormal while using Galcanezumab-gnlm
FDA FAERS contains adverse-event reports in which Galcanezumab-gnlm and feeling abnormal appear together. This does not establish that Galcanezumab-gnlm caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Head Discomfort while using Galcanezumab-gnlm
FDA FAERS contains adverse-event reports in which Galcanezumab-gnlm and head discomfort appear together. This does not establish that Galcanezumab-gnlm caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Headache while using Galcanezumab-gnlm
FDA FAERS contains adverse-event reports in which Galcanezumab-gnlm and headache appear together. This does not establish that Galcanezumab-gnlm caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Heart Rate Increased while using Galcanezumab-gnlm
FDA FAERS contains adverse-event reports in which Galcanezumab-gnlm and heart rate increased appear together. This does not establish that Galcanezumab-gnlm caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Hives while using Galcanezumab-gnlm
FDA FAERS contains adverse-event reports in which Galcanezumab-gnlm and hives appear together. This does not establish that Galcanezumab-gnlm caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Insomnia while using Galcanezumab-gnlm
FDA FAERS contains adverse-event reports in which Galcanezumab-gnlm and insomnia appear together. This does not establish that Galcanezumab-gnlm caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Itching while using Galcanezumab-gnlm
FDA FAERS contains adverse-event reports in which Galcanezumab-gnlm and itching appear together. This does not establish that Galcanezumab-gnlm caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Malaise while using Galcanezumab-gnlm
FDA FAERS contains adverse-event reports in which Galcanezumab-gnlm and malaise appear together. This does not establish that Galcanezumab-gnlm caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Migraine while using Galcanezumab-gnlm
FDA FAERS contains adverse-event reports in which Galcanezumab-gnlm and migraine appear together. This does not establish that Galcanezumab-gnlm caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Muscle Spasms while using Galcanezumab-gnlm
FDA FAERS contains adverse-event reports in which Galcanezumab-gnlm and muscle spasms appear together. This does not establish that Galcanezumab-gnlm caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Myalgia while using Galcanezumab-gnlm
FDA FAERS contains adverse-event reports in which Galcanezumab-gnlm and myalgia appear together. This does not establish that Galcanezumab-gnlm caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Nausea while using Galcanezumab-gnlm
FDA FAERS contains adverse-event reports in which Galcanezumab-gnlm and nausea appear together. This does not establish that Galcanezumab-gnlm caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Pain while using Galcanezumab-gnlm
FDA FAERS contains adverse-event reports in which Galcanezumab-gnlm and pain appear together. This does not establish that Galcanezumab-gnlm caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Palpitations while using Galcanezumab-gnlm
FDA FAERS contains adverse-event reports in which Galcanezumab-gnlm and palpitations appear together. This does not establish that Galcanezumab-gnlm caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Rash while using Galcanezumab-gnlm
FDA FAERS contains adverse-event reports in which Galcanezumab-gnlm and rash appear together. This does not establish that Galcanezumab-gnlm caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Shortness of breath while using Galcanezumab-gnlm
FDA FAERS contains adverse-event reports in which Galcanezumab-gnlm and shortness of breath appear together. This does not establish that Galcanezumab-gnlm caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Skin redness while using Galcanezumab-gnlm
FDA FAERS contains adverse-event reports in which Galcanezumab-gnlm and skin redness appear together. This does not establish that Galcanezumab-gnlm caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Sleepiness while using Galcanezumab-gnlm
FDA FAERS contains adverse-event reports in which Galcanezumab-gnlm and sleepiness appear together. This does not establish that Galcanezumab-gnlm caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Tingling or pins and needles while using Galcanezumab-gnlm
FDA FAERS contains adverse-event reports in which Galcanezumab-gnlm and tingling or pins and needles appear together. This does not establish that Galcanezumab-gnlm caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Tinnitus while using Galcanezumab-gnlm
FDA FAERS contains adverse-event reports in which Galcanezumab-gnlm and tinnitus appear together. This does not establish that Galcanezumab-gnlm caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Tremor while using Galcanezumab-gnlm
FDA FAERS contains adverse-event reports in which Galcanezumab-gnlm and tremor appear together. This does not establish that Galcanezumab-gnlm caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Vertigo while using Galcanezumab-gnlm
FDA FAERS contains adverse-event reports in which Galcanezumab-gnlm and vertigo appear together. This does not establish that Galcanezumab-gnlm caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Vision Blurred while using Galcanezumab-gnlm
FDA FAERS contains adverse-event reports in which Galcanezumab-gnlm and vision blurred appear together. This does not establish that Galcanezumab-gnlm caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Vomiting while using Galcanezumab-gnlm
FDA FAERS contains adverse-event reports in which Galcanezumab-gnlm and vomiting appear together. This does not establish that Galcanezumab-gnlm caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Weakness while using Galcanezumab-gnlm
FDA FAERS contains adverse-event reports in which Galcanezumab-gnlm and weakness appear together. This does not establish that Galcanezumab-gnlm caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Weight Decreased while using Galcanezumab-gnlm
FDA FAERS contains adverse-event reports in which Galcanezumab-gnlm and weight decreased appear together. This does not establish that Galcanezumab-gnlm caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Weight Increased while using Galcanezumab-gnlm
FDA FAERS contains adverse-event reports in which Galcanezumab-gnlm and weight increased appear together. This does not establish that Galcanezumab-gnlm caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →